Search Medical Condition
Please enter condition
Please choose location from dropdown

Dunedin, Florida Clinical Trials

A listing of Dunedin, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (412) clinical trials

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Phase

0.0 miles

Learn More »

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

This is a prospective, multicenter, open-label study assessing the efficacy and safety of RBX2660 as an adjunct to antibiotics for the treatment of recurrent CDI. The primary assessments for this study are (i) to assess efficacy as the absence of CDI diarrhea without the need for retreatment with C. difficile ...

Phase

0.0 miles

Learn More »

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities: Argentina Brazil Bulgaria Canada Colombia Czech Republic Denmark France Germany Hungary India Israel Japan Mexico Netherlands Poland Romania Russian Federation Slovakia South Africa Spain Ukraine United Kingdom United States

Phase

0.0 miles

Learn More »

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

PSOLAR is an 8 year registry study. A registry is an observational study that evaluates the status of a disease. This registry study will only include patients who volunteer to take part. About 4000 infliximab-exposed patients, 4000 ustekinumab-exposed patients and as well as a comparable number of patients (4000) on ...

Phase N/A

0.0 miles

Learn More »

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

The registry will be used to evaluate, describe, and document the safety of target-specific anticoagulant agents (and other antithrombotic agents) in patients with Atrial Fibrillation (AF), the clinical outcomes associated with their use, the treatment patterns and clinical course of patients with AF, including those who undergo cardiac procedures of ...

Phase N/A

0.0 miles

Learn More »

Diuretic Comparison Project

Over 1 million Veterans are prescribed a thiazide-type diuretic each year; over 95% receive hydrochlorothiazide, and fewer than 2.5% receive chlorthalidone. Both medications are thiazide-type diuretics that have been used for more than 50 years and are considered first-line treatment for hypertension. Indirect evidence has been accumulating, however, that chlorthalidone ...

Phase

0.0 miles

Learn More »

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

This is a prospective, randomized, double-blind, placebo-controlled, investigation of a six week course of adjunctive rifampin vs. adjunctive matched placebo (riboflavin) added to backbone antibacterial therapy for the treatment of diabetic foot osteomyelitis. Backbone antibacterial therapy will be with single or multiple agents selected by the clinical treatment team based ...

Phase

0.0 miles

Learn More »

Optimal Treatment for Recurrent Clostridium Difficile

Clostridium difficile is the most common cause of healthcare-associated infectious diarrhea among adults in industrialized countries. In addition to diarrhea, C. difficile infection (CDI) may also result in serious complications such as shock, toxic megacolon, colectomy, and death. The Centers for Disease Control and Prevention (CDC) has estimated C. difficile ...

Phase

0.0 miles

Learn More »

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with ...

Phase

1.69 miles

Learn More »